263 related articles for article (PubMed ID: 36119108)
1. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
Front Immunol; 2022; 13():940801. PubMed ID: 36119108
[TBL] [Abstract][Full Text] [Related]
2. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
3. Immune infiltration and clinical significance analyses of the cancer-associated fibroblast-related signature in skin cutaneous melanoma.
Cen X; Li M; Yao A; Zheng Y; Lai W
J Gene Med; 2024 Jan; 26(1):e3614. PubMed ID: 37847069
[TBL] [Abstract][Full Text] [Related]
4. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
6. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
7. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors.
Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF
J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
9. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
10. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer.
Liu H; Zhou L; Cheng H; Wang S; Luan W; Cai E; Ye X; Zhu H; Cui H; Li Y; Chang X
Chin Med J (Engl); 2023 Dec; 136(24):2974-2982. PubMed ID: 37284741
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
12. Integrative Analysis From Multicenter Studies Identifies a WGCNA-Derived Cancer-Associated Fibroblast Signature for Ovarian Cancer.
Feng S; Xu Y; Dai Z; Yin H; Zhang K; Shen Y
Front Immunol; 2022; 13():951582. PubMed ID: 35874760
[TBL] [Abstract][Full Text] [Related]
13. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
14. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC.
Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X
Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552
[TBL] [Abstract][Full Text] [Related]
15. Effect of activating cancer-associated fibroblasts biomarker TNC on immune cell infiltration and prognosis in breast cancer.
Huang T; Lu C; Zhang Y; Lin BY; Zhang ZJ; Zhu D; Wang L; Lu Y
Ann Med; 2023; 55(2):2250987. PubMed ID: 38375814
[TBL] [Abstract][Full Text] [Related]
16. Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis.
Wu Q; He X; Liu J; Ou C; Li Y; Fu X
Cancer Cell Int; 2023 Sep; 23(1):223. PubMed ID: 37777759
[TBL] [Abstract][Full Text] [Related]
17. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
19. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
20. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
